Capital Fund Management (CFM)’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,500	Closed	-$5.35M	–	2269
2024 Q3	$5.35M	Buy	+11,500	New	+$5.52M	0.01%	990
2024 Q2	–	Sell	-13,500	Closed	-$5.64M	–	2194
2024 Q1	$5.64M	Buy	+13,500	New	+$5.71M	0.02%	995
2023 Q4	–	Sell	-41,300	Closed	-$14.4M	–	2313
2023 Q3	$14.4M	Buy	+41,300	New	+$14.4M	0.05%	472
2020 Q2	–	Sell	-6,500	Closed	-$1.55M	–	1602
2020 Q1	$1.55M	Buy	+6,500	New	+$1.49M	0.02%	608
2018 Q1	–	Sell	-2,500	Closed	-$375K	–	2206
2017 Q4	$375K	Sell	2,500 -2,200	-47%	-$326K	﹤0.01%	1552
2017 Q3	$715K	Buy	+4,700	New	+$707K	0.01%	1077
2014 Q4	–	Sell	-1,800	Closed	-$202K	–	1825
2014 Q3	$202K	Buy	+1,800	New	+$171K	﹤0.01%	1455
2013 Q3	–	Sell	-33,300	Closed	-$2.66M	–	1925
2013 Q2	$2.66M	Buy	+33,300	New	+$2.45M	0.04%	543

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Fund Management (CFM)'s VRTX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q2 2026, selling an estimated $23M and leaving 71,088 shares worth $35.3M. The position accounts for 0.16% of the portfolio, ranked #145.

Capital Fund Management (CFM) first reported a position in VRTX in Q2 2013 and has held it in 25 quarters since. The position peaked at $54.9M in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capital Fund Management (CFM) held 71,088 shares of Vertex Pharmaceuticals worth $35.3M as of Q2 2026.
Capital Fund Management (CFM) sold 51,846 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23M.
Vertex Pharmaceuticals made up 0.16% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #145 holding.
Capital Fund Management (CFM) first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
Capital Fund Management (CFM)'s Vertex Pharmaceuticals position peaked at $54.9M in Q1 2026.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.